• Embed Doc
  • Readcast
  • Collections
  • CommentGo Back
 
ORIGINAL INVESTIGATION
Vasopressin, Epinephrine, and Corticosteroidsfor In-Hospital Cardiac Arrest
Spyros D. Mentzelopoulos, MD, PhD; Spyros G. Zakynthinos, MD, PhD; Maria Tzoufi, MD, PhD;Nikos Katsios, MD; Androula Papastylianou, MD; Sotiria Gkisioti, MD; Anastasios Stathopoulos, MD; Androniki Kollintza, PhD; Elissavet Stamataki, MD, PhD; Charis Roussos, MD, PhD
Background
:
Animal data on cardiac arrest showedimproved long-term survival with combined vasopres-sin-epinephrine. In cardiac arrest, cortisol levels arerelatively low during and after cardiopulmonary resus-citation. We hypothesized that combined vasopressin-epinephrine and corticosteroid supplementation dur-ing and after resuscitation may improve survival inrefractory in-hospital cardiac arrest.
Methods
:
We conducted a single-center, prospective,randomized,double-blind,placebo-controlled,parallel-group trial. We enrolled 100 consecutive patients withcardiac arrest requiring epinephrine according to cur-rentresuscitationguidelines.Patientsreceivedeitherva-sopressin(20IUpercardiopulmonaryresuscitationcycle)plus epinephrine (1 mg per resuscitation cycle) (studygroup; n=48) or isotonic sodium chloride solution pla-ceboplusepinephrine(1mgperresuscitationcycle)(con-trol group; n=52) for the first 5 resuscitation cycles af-ter randomization, followed by additional epinephrineif needed. On the first resuscitation cycle, study grouppatientsreceivedmethylprednisolonesodiumsuccinate(40mg)andcontrolsreceivedsalineplacebo.Postresus-citation shock was treated with stress-dose hydrocorti-sone sodium succinate (300 mg daily for 7 days maxi-mum,withgradualtaper)(27patientsinthestudygroup)orsalineplacebo(15patientsinthecontrolgroup).Pri-mary end points were return of spontaneous circulationfor15minutesorlongerandsurvivaltohospitaldischarge.
Results
:
Studygrouppatientsvscontrolshadmorefre-quent return of spontaneous circulation (39 of 48 pa-tients [81%] vs 27 of 52 [52%];
P
=.003) and improvedsurvivaltohospitaldischarge(9[19%]vs2[4%];
P
=.02).Studygrouppatientswithpostresuscitationshockvscor-responding controls had improved survival to hospitaldischarge(8of27patients[30%]vs0of15[0%];
P
=.02),improvedhemodynamicsandcentralvenousoxygensatu-ration,andmoreorganfailure–freedays.Adverseeventswere similar in the 2 groups.
Conclusion
:
In this single-center trial, combined vaso-pressin-epinephrine and methylprednisolone duringresuscitation and stress-dose hydrocortisone in post-resuscitation shock improved survival in refractory in-hospital cardiac arrest.
Trial Registration
:
clinicaltrials.gov Identifier:NCT00411879
 Arch Intern Med. 2009;169(1):15-24
T
HEINCIDENCEOFIN
-
HOSPITAL
cardiac arrest is 1 to 5 per1000 patient admissions.
1
Survivaltohospitaldischargeisapproximately20%.
1
Sur-vival after refractory cardiac arrest, ie, re-fractory ventricular fibrillation/pulselessventriculartachycardiaorasystole/pulselesselectricalactivity,rangesfrom5%to15%.
2
Innonsurvivorsofcardiopulmonaryre-suscitation (CPR), the plasma vasopres-sin level is lower than in CPR survivors.
3
Vasopressin acts directly via V
1
receptorson vascular contractile elements. In car-diac arrest, vasopressin is released as ad- junct vasopressor to epinephrine.
4
Re-centanimaldatashowedimprovedsurvivalandpostresuscitationneurologicstatusaf-ter treatment with vasopressin-epineph-rine compared with epinephrine alone.
5
Combination treatment was associatedwithfewerpostresuscitationcardiovascu-lar complications and similar neurologicstatus relative to vasopressin alone.
5
Relativetootherstressstates,cardiacar-restisassociatedwithlowercortisollevelsduring and after CPR.
4,6,7
Return of spon-taneous circulation is associated withplasma cytokine elevation,
4,6
endotox-emia,
4
coagulopathy,
4
andadrenalinsuffi-ciency contributing to postresuscitationshock.
4,7
Corticosteroid supplementationduring and after CPR might confer ben-efitswithrespecttohemodynamics,inten-sity of postresuscitation systemic inflam-matoryresponse,andorgandysfunction.
4,7
 Wehypothesizedthat,inrefractoryin-hospital cardiac arrest, treatment withcombined vasopressin-epinephrine dur-ingCPRandcorticosteroidsupplementa-tionduringandafterCPR,comparedwithepinephrinealoneduringCPRandnocor-
Author Affiliations:
FirstDepartment of Intensive CareMedicine, University of AthensMedical School(Drs Mentzelopoulos,Zakynthinos, Tzoufi, Kollintza,and Roussos); and Departmentof Anesthesiology, EvaggelismosGeneral Hospital (Drs Katsios,Papastylianou, Gkisioti,Stathopoulos, and Stamataki),Athens, Greece.
(REPRINTED) ARCH INTERN MED/VOL 169 (NO. 1), JAN 12, 2009 WWW.ARCHINTERNMED.COM
15
©2009 American Medical Association. All rights reserved.
 at FACULTY OF MEDICINE - LIBRARY, on January 13, 2009www.archinternmed.comDownloaded from 
 
ticosteroidsupplementation,may(1)facilitatereturnof spontaneous circulation, (2) attenuate postresuscita-tionsystemicinflammatoryresponseandcardiacarrest–associatedorganinjuries,and(3)improvesurvivaltohos-pital discharge.
METHODS
PATIENTS
 We conducted our study in the intensive/coronary care units(ICUs/CCUs), emergency department, general wards, and op-erating rooms of Evaggelismos Hospital, a tertiary care teach-inghospital.Thepatienteligibilitycriterionwasrefractorycar-diacarrest,definedasepinephrinerequirementforventricularfibrillation/ventricular tachycardia or asystole/pulseless elec-trical activity according to the European Resuscitation Coun-cilGuidelinesforResuscitation2005.
8
Exclusioncriteriawereage younger than 18 years, terminal illness
2
or do-not-resuscitate status, cardiac arrest due to exsanguination, car-diac arrest before hospital admission, treatment with intrave-nous corticosteroids before the cardiac arrest, and previousenrollmentinorexclusionfromthecurrentstudy.ConsentwasnotobtainedfortheCPR-drugcombination.
2
Thepatientsandtheir families were informed about the trial.
9
Informed, writ-tennext-of-kinconsentandnonwrittenpatientconsent(when-everfeasible)wereobtainedforstress-dosehydrocortisoneso-dium succinate in postresuscitation shock and for bloodsampling to determine plasma cytokine levels. The ScientificCouncil of Evaggelismos Hospital approved the study.
STUDY DESIGN AND PROTOCOL
This was a single-center, prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial. Groupallocationwasconductedbythedirectorofthehospital’sphar-macy with the Research Randomizer (http://www.randomizer.org). Random numbers from 1 to 100 were generated in setsof 4. Each number of each set was unique and was assigned to1 ofthe100 consecutivelyenrolledpatientsashisorhercode.Vasopressinandmethylprednisolonewerepreparedbythehos-pital’spharmacyinidentical,preloaded5-mLsyringesandplacedalongwithepinephrineampulesinboxesbearingpatientcodes(for details, see the supplemental material available at http: //www.mentzelopoulos-et-al.com). After patient randomiza-tion, a box was opened and study drugs were injected intrave-nously according to protocol. Drug injection was followed by10 mL of isotonic sodium chloride solution.
CPR Interventions
Adult inpatients with cardiac arrest induced by ventricular fi-brillation/ventricular tachycardia not responsive to 2 defibril-lations separated by 2 to 3 minutes of CPR
8
or patients withasystole/pulseless electrical activity were randomized to re-ceiveeithercombinedvasopressin(20IUperCPRcycle;Mon-arch Pharmaceuticals, Bristol, Tennessee) and epinephrine(1 mg per CPR cycle; Demo, Athens, Greece) (study group),or isotonic sodium chloride solution placebo and epinephrine(1mgperCPRcycle)(controlgroup),forthefirst5CPRcyclesafter randomization. Forty milligrams of methylprednisolonesodium succinate (Pfizer, Athens, Greece) and isotonic so-dium chloride solution placebo were administered during thefirst CPR cycle after randomization to study group and con-trol group patients, respectively. If return of spontaneous cir-culation was not achieved on completion of the experimentaltreatment, CPR was continued according to current guide-lines.
8
Our protocol is schematically presented in
Figure 1
.Experimental drug stability in the syringes was confirmed byhigh-performanceliquidchromatography(seetheonlinesupple-mental material). Advanced life support was conducted ac-cording to current standards
8
(also described in the onlinesupplemental material).
Postresuscitation Shock
At 4 hours after resuscitation, surviving study group patientswith postresuscitation shock received stress-dose hydrocorti-sonesodiumsuccinate(300mgdailyfor7daysmaximum,andgradual taper; Pfizer).
10
Hydrocortisone was available in vials
ROSC ExclusionUnresponsive?ShockableVF/pulseless VTOne monophasicshock of 360 JCPR for 2-3 minfollowed byassessmentof rhythmROSC ExclusionRandomizationDuring current CPR cycleIV administration ofDuring each of 4subsequent CPR cyclesIV administration ofContinuation of CPRaccording toERC Guidelines 20054 h after ROSCAssessment forpostresuscitation shock1 min after startof 2nd CPR cycle1 min after startof 1st CPR cycleIsotonic sodium chloridesolution placeboEpinephrine, 1 mgSaline placebo(Control group)Vasopressin, 20 IUEpinephrine, 1 mgMethylprednisolone 40 mg(Study group)Isotonic sodium chloridesolution placeboEpinephrine, 1 mgIsotonic sodium chloridesolution placeboNo furtherinterventionStress dose ofhydrocortisoneVasopressin, 20 IUEpinephrine, 1 mgNonshockablePEA/asystoleEstablishment of airway patencyAssessment for signs of lifeCPR (30 compressions; 2 ventilations)Attachment of defibrillator/monitorCalling ofresuscitationteam
 u i    g  e  a  c h   c  y  c l    e  C f   o 2   3 mi   f   o l   l    o w e  d   b   y  a  s  s  e  s  s m e t   o f  h   y t  h  m
    D   u   r    i   n   g   e   a   c    h   c   y   c    l   e    C    P    R   f   o   r    2  -    3   m    i   n   f   o    l    l   o   w   e    d    b   y   a   s   s   e   s   s   m   e   n   t   o   f   r    h   y   t    h   m
YesNoAssessmentof rhythmOne monophasicshock of 360 JYesNo
Figure 1.
Schematic diagram of the cardiopulmonary resuscitation (CPR)procedures and study protocol. ERC indicates European ResuscitationCouncil; IV, intravenous; PEA, pulseless electrical activity; ROSC, return ofspontaneous circulation; VF, ventricular fibrillation; VT, ventricular tachycardia.
(REPRINTED) ARCH INTERN MED/VOL 169 (NO. 1), JAN 12, 2009 WWW.ARCHINTERNMED.COM
16
©2009 American Medical Association. All rights reserved.
 at FACULTY OF MEDICINE - LIBRARY, on January 13, 2009www.archinternmed.comDownloaded from 
 
containing 100 mg of hydrocortisone sodium succinate pow-der. Each daily dose was diluted in 100 mL of isotonic sodiumchloride solution at the hospital’s pharmacy and administeredtostudygrouppatientsasacontinuousinfusion.Onvasopres-sor cessation or on day 8 after cardiac arrest, the daily hydro-cortisonesodiumsuccinatedosewasconsecutivelyreducedto200 mg and 100 mg and then discontinued (see the onlinesupplementalmaterial).Controlgrouppatientswithpostresus-citation shock received daily infusions of 100 mL of isotonicsodiumchloridesolutionplacebo.Isotonicsodiumchlorideso-lution infusion bags bore the patient codes.
DEFINITIONS
Circulatory failure
was defined as inability to maintain meanarterial pressure greater than 70 mm Hg without using vaso-pressors after volume loading.
10
Respiratory failure
was de-fined as a ratio of arterial oxygen partial pressure to inspiredoxygen fraction of 200 mm Hg or less.
Coagulation failure
wasdefined as a platelet count of 50
10
3
 /µL or less.
Hepatic fail-ure
was defined as serum bilirubin concentration of 6 mg/dL(toconverttomicromolesperliter,multiplyby17.104)orless.
Renalfailure
wasdefinedasserumcreatininelevelof3.5mg/dL(toconverttomicromolesperliter,multiplyby88.4)orgreaterand/or requirement of renal replacement therapy.
Neurologic failure
was defined as a Glasgow Coma Score of 9 or less.After resuscitation, cardiac arrest–induced cardiac and mi-crocirculatory dysfunction lasts approximately 24 hours.
6
Postresuscitation shock was defined as sustained (
4 hours),newpostarrestcirculatoryfailureorpostarrestneedforatleasta 50% increase in any prearrest vasopressor/inotropic supporttargeted to maintain mean arterial pressure above 70 mm Hg.
DOCUMENTATION AND PATIENT FOLLOW-UP
AttemptsatCPRweredocumentedaccordingtotheUtsteinstyle.
9
Additional data comprised periarrest arterial pressure, gas ex-change,electrolyteandlactatelevels,vasopressor/inotropicsup-port, and intravenous fluids given. Daily follow-up was con-ducted by 4 blinded investigators (N.K., S.G., A.P., and A.S.).Follow-uptoday60aftercardiacarrestincludedmedication,or-gan or system failures, and ventilator-free days. Morbidity andcomplicationsthroughoutICU/CCUandhospitalstayandtimesto ICU/CCU and hospital discharge were also recorded. En-coded patient data were entered into a database by 2 investiga-tors (N.K. and S.G.) and independently cross-checked by an-other 2 investigators (A.P. and A.S.). Data were independentlyscrutinized by a steering committee.
PLASMA CYTOKINE CONCENTRATIONS
Venipuncturebloodsampleswereobtainedonday0(at6hoursafter randomization) from the last 35 surviving patients withpostresuscitation shock; additional blood samples were ob-tainedondays1,3,and7afterrandomization.Serumconcen-trationsoftumornecrosisfactor,interleukin(IL)-1
,IL-6,IL-8,and IL-10 were measured by an enzyme-linked immunosor-bent assay (Quantikine; R&D Systems Europe Ltd, Abingdon,England) according to manufacturer instructions.
STUDY END POINTS
Primaryendpointswerereturnofspontaneouscirculationfor15 minutes or longer and survival to hospital discharge, de-fined as presence of an attending physician discharge order tohomeortoarehabilitationfacility.Secondaryendpointswerearterial pressure during and 15 to 20 minutes after CPR, in-tensity of postarrest systemic inflammatory response, numberof organ failure–free days until completion of follow-up, andcerebralperformanceaccordingtotheGlasgow-Pittsburghscaleathospitaldischarge(seeonlinesupplementalmaterialforde-tails on determination of end points).
STATISTICAL ANALYSIS
Initial rhythm is asystole in 75% to 80% of the refractory car-diac arrests occurring in our hospital. Sample-size calculation(G
*
Power version 3.0.8; Heinrich Heine University, Düssel-dorf, Germany) was based on a possible, drug-related, overall3.1-fold improvement in survival to hospital discharge of thestudy group vs the control group. Survival improvement wasexpected mainly for patients with asystole.
9
Thus, our overallprediction was equivalent to an experimental treatment–induced 3.8-fold rise in the survival of patients with asystole.This corresponds to an improvement of 22.6% relative to a re-centlyreportedvasopressin-induced3.1-foldriseinsurvivalaf-terasystoliccardiacarrest.
9
Predictedoverallsurvivalofthecon-trol group was 5%.
2
Calculated
2
effect size was 0.34. For an
value of .05 and a power of 0.80, the estimated sample sizewas 68 (ie, 34 patients per group). The inclusion of 100 pa-tients resulted in a safety margin of 32 of 68 (47%).An intention-to-treat analysis was conducted with SPSS ver-sion12.0statisticalsoftware(SPSSInc,Chicago,Illinois).Dataarereportedasmean(SD),median(interquartilerange[IQR]),ornum-ber(percentage),unlessotherwisespecified.Distributionnormal-itywastestedbytheKolmogorov-Smirnovtest.Dichotomousandcategoricalvariableswerecomparedbythe
2
orFisherexacttest.Continuousvariableswerecomparedbya2-tailed,independent-samples
t
testortheMann-Whitneyexacttest.Inpostresuscitationshock,weusedlinearmixed-modelanaly-sis to determine the overall effects of group, time, and their in-teraction(group
time)onlog-transformedplasmacytokinecon-centrationsthroughoutthefirst7daysafterrandomization.Theeffectsofgroup,time,andgroup
timeon(1)averagedailycen-tral venous oxygen saturation and arterial blood lactate (mea-suredevery12hours),meanarterialpressure(recordedevery3hours), and infusion rates of vasopressors; (2) daily fluid bal-ance; and (3) hemoglobin concentration (measured every 24hours) were also analyzed for the first 10 days after randomiza-tion.Fixed-effectssignificancewasdeterminedbythe
F
test.Modelselectionwasbasedontheminimumvaluesof−2restrictedlog-likelihoodandAkaikeinformationcriteria.Between-groupcom-parisonsatindividual,consecutivetimepointswereconductedwith the independent-samples
t
test;
P
values were not cor-rected for multiple comparisons.SurvivalwasanalyzedbytheKaplan-Meiermethod,andsur-vival data were compared by (1) the Fisher exact test to deter-mine any nonrandom association between group and survivalto hospital discharge and (2) the log-rank test to test the nullhypothesis that the probability of death did not differ betweenthestudyandcontrolgroupsthroughoutpatientfollow-up.Uni-variate and multivariate backward-stepwise Cox regressionanalysis was used to identify independent predictors of deathandtodeterminetherespectiveproportionalhazardsandtheir95% confidence intervals. Variable entry and removal criteriawere0.05and0.10,respectively.Reported
P
valuesare2sided.Statistical significance was set at
P
.05.
RESULTS
From June 8, 2006, to March 16, 2007, there were 139potentially eligible patients with cardiac arrest. Overallsurvival to hospital discharge was 37 of 139 patients
(REPRINTED) ARCH INTERN MED/VOL 169 (NO. 1), JAN 12, 2009 WWW.ARCHINTERNMED.COM
17
©2009 American Medical Association. All rights reserved.
 at FACULTY OF MEDICINE - LIBRARY, on January 13, 2009www.archinternmed.comDownloaded from 
of 00

Leave a Comment

You must be to leave a comment.
Submit
Characters: ...
You must be to leave a comment.
Submit
Characters: ...